

SANOFI PASTEUR R&D PORTFOLIO

- 14 vaccines in development ⁽¹⁾

PHASE I	PHASE II	PHASE III	SUBMITTED
<p>Rotavirus Live Attenuated Tetravalent Rotavirus oral vaccine</p>	<p>ACAM-Cdiff <i>Clostridium difficile</i> Toxoid vaccine</p>	<p>DTP-HepB-Polio-Hib Pediatric hexavalent vaccine</p>	<p>Hexaxim™ / New hexavalent vaccine DTP-HepB-Polio-Hib vaccine</p>
<p><i>Streptococcus pneumoniae</i> Meningitis & pneumonia vaccine</p>	<p>Rabies VRVg Purified vero rabies vaccine</p>	<p>Quadracel® Diphtheria, tetanus, pertussis & polio vaccine; 4-6 y of age</p>	<p>Fluzone® QIV IM Quadrivalent inactivated influenza vaccine</p>
<p><i>Pseudomonas aeruginosa</i> Antibody fragment product Prevention of ventilator-associated pneumonia</p>	<p>Meninge ACYW conj. 2nd generation meningococcal conjugate Infant vaccine</p>	<p>Dengue Mild-to-severe dengue fever vaccine</p>	
<p>Tuberculosis Recombinant subunit vaccine</p>		<p>Vaxigrip® QIV IM Quadrivalent inactivated influenza vaccine</p>	
		<p>Fluzone® QIV ID Quadrivalent inactivated influenza vaccine Intradermal</p>	

(1) As of February 7, 2013, from phase I to "submitted"